Save to Existing Project
Save to a New Project
ELC GROUP S.r.o.
Abiraterone Acetate is the generic form of branded drug ZYTIGAÂ® used along with prednisone to treat men with castration-resistant prostate cancer (cancer that is resistant to medical or surgical treatments) that has spread to other parts of the...
Abiraterone acetate is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer. It has received FDA approval on 28 April 2011, EMA approval on 23 September 2011, MHRA approval on 5 September 2011 and TGA approval on 1 March 2012 for this indication. Zytiga has been one of Johnson & Johnson’s best new drug launches with global sales totalling $2.2 billion in 2015.
Type of Business Relationship Sought
Last Updated Nov 2016